CL2008003507A1 - Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. - Google Patents

Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.

Info

Publication number
CL2008003507A1
CL2008003507A1 CL2008003507A CL2008003507A CL2008003507A1 CL 2008003507 A1 CL2008003507 A1 CL 2008003507A1 CL 2008003507 A CL2008003507 A CL 2008003507A CL 2008003507 A CL2008003507 A CL 2008003507A CL 2008003507 A1 CL2008003507 A1 CL 2008003507A1
Authority
CL
Chile
Prior art keywords
nachr
opipramol
nicotine
disorder
acetylcholine receptor
Prior art date
Application number
CL2008003507A
Other languages
English (en)
Inventor
Heldman Eliahu
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40380297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of CL2008003507A1 publication Critical patent/CL2008003507A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Composición farmacéutica que comprende un agonista nicotínico y un inhibidor de la desensibilización del receptor de acetilcolina nicotínico (nachr); kit farmacéutico en forma de parche trandérmico; útil para el tratamiento de enfermedades del SNC, enfermedades del SNP y en el tratamiento de la adicción al tabaco.
CL2008003507A 2007-11-26 2008-11-25 Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. CL2008003507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99016107P 2007-11-26 2007-11-26

Publications (1)

Publication Number Publication Date
CL2008003507A1 true CL2008003507A1 (es) 2009-11-27

Family

ID=40380297

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003507A CL2008003507A1 (es) 2007-11-26 2008-11-25 Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.

Country Status (21)

Country Link
US (5) US8273731B2 (es)
EP (1) EP2224917B1 (es)
JP (1) JP5456687B2 (es)
KR (1) KR101613742B1 (es)
CN (1) CN101925352B (es)
AR (1) AR069752A1 (es)
AU (1) AU2008331102B2 (es)
BR (1) BRPI0819911A2 (es)
CA (1) CA2744736C (es)
CL (1) CL2008003507A1 (es)
CY (1) CY1119768T1 (es)
DK (1) DK2224917T3 (es)
ES (1) ES2642873T3 (es)
HR (1) HRP20171476T1 (es)
HU (1) HUE035105T2 (es)
LT (1) LT2224917T (es)
MX (1) MX2010005804A (es)
PL (1) PL2224917T3 (es)
PT (1) PT2224917T (es)
SI (1) SI2224917T1 (es)
WO (1) WO2009069126A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
JP2011530222A (ja) 2008-08-01 2011-12-15 ゾラン コーポレイション 雑音除去のための統合時間フィルタを備えたビデオエンコーダ
US9801865B2 (en) * 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
PL2701681T3 (pl) 2011-04-29 2017-03-31 Moberg Pharma Ab Kompozycje farmaceutyczne zawierające środek miejscowo znieczulający, taki jak bupiwakaina, do podawania miejscowego do jamy ustnej lub gardła
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3116475T3 (pl) 2014-03-13 2021-02-08 Neuroderm Ltd Kompozycje inhibitora dekarboksylazy dopa
US20170216273A1 (en) * 2014-05-29 2017-08-03 Jory F. Goodman Nicotine Derivatives and Methods of Use
CA2960626A1 (en) * 2014-09-18 2016-03-24 Neuroderm, Ltd. Opipramol patch
DK3209295T4 (da) * 2014-10-20 2024-02-26 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
KR102627987B1 (ko) 2014-12-05 2024-01-22 쥴 랩스, 인크. 교정된 투여량 제어
KR102512777B1 (ko) 2016-04-07 2023-03-23 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
US10292977B2 (en) * 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
MX2018012439A (es) 2016-04-12 2019-02-21 Solis Herrera Arturo Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.
KR20180058644A (ko) * 2016-11-24 2018-06-01 에스케이케미칼 주식회사 바레니클린 서방성 제제 및 이의 제조 방법
US11260050B2 (en) 2017-02-16 2022-03-01 United States Government As Represented By The Department Of Veterans Affairs Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological
US20200000822A1 (en) * 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
AU2018364738A1 (en) * 2017-11-10 2020-05-28 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
LU101519B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069094A (en) * 1987-09-08 1991-12-03 Birkestrand Orville J Tube end finishing machine
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
ATE207357T1 (de) * 1992-05-18 2001-11-15 Pharmaco Behavioral Ass Verwendung von cotinin zur linderung des tabakentzugssyndrom
JPH09262287A (ja) * 1996-03-28 1997-10-07 Terumo Corp 薬液注入装置
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
DE10134038A1 (de) 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
US20030119879A1 (en) 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
ES2311756T3 (es) * 2002-12-18 2009-02-16 Algorx Administracion de la capsiacina.
ITMI20030828A1 (it) 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione dell'opipramolo.
AU2004283431B2 (en) * 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20050191349A1 (en) 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
WO2005115471A2 (en) 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US20060142349A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
US20080014252A1 (en) * 2006-07-14 2008-01-17 Delprete Keith Topical compositions with long lasting effect
WO2008011484A2 (en) 2006-07-18 2008-01-24 Bethesda Pharmacology Associates, Llc Nicotinic desensitizers and methods of selecting, testing, and using them
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.

Also Published As

Publication number Publication date
AU2008331102B2 (en) 2014-04-10
PT2224917T (pt) 2017-10-17
EP2224917B1 (en) 2017-07-05
AR069752A1 (es) 2010-02-17
ES2642873T3 (es) 2017-11-20
US8273731B2 (en) 2012-09-25
SI2224917T1 (sl) 2017-12-29
EP2224917A1 (en) 2010-09-08
JP5456687B2 (ja) 2014-04-02
HUE035105T2 (en) 2018-05-02
CY1119768T1 (el) 2018-06-27
BRPI0819911A2 (pt) 2017-06-13
US20170128432A1 (en) 2017-05-11
PL2224917T3 (pl) 2018-02-28
KR101613742B1 (ko) 2016-04-19
CA2744736C (en) 2015-06-09
MX2010005804A (es) 2010-11-30
US20090149446A1 (en) 2009-06-11
JP2011504490A (ja) 2011-02-10
CN101925352A (zh) 2010-12-22
AU2008331102A1 (en) 2009-06-04
DK2224917T3 (en) 2017-10-16
CN101925352B (zh) 2016-03-16
HRP20171476T1 (hr) 2017-12-15
US20150306109A1 (en) 2015-10-29
KR20100105841A (ko) 2010-09-30
US8921356B2 (en) 2014-12-30
CA2744736A1 (en) 2009-06-04
WO2009069126A1 (en) 2009-06-04
LT2224917T (lt) 2017-12-27
US20180303818A1 (en) 2018-10-25
US20130172321A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
CL2008003507A1 (es) Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
GT200900023A (es) Formas farmacéuticas de dosificación oral que contienen un analgésico opioide.
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
BRPI0714712B8 (pt) dispositivo para administração de fármaco
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
ATE474564T1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CL2007001554A1 (es) Compuestos derivados de pirido [3,2-e]pirazinas;inhibidoras de pde10;procedimiento de preparacion;composicion farmaceutica que comprende; kit farmaceutico; uso para preparar de un medicamento para tratar o prevenir trastornos asociados a la hiperactividad de pde10 y/o trastornos en los que inhibir la pde10 es de valor.
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
CL2008001740A1 (es) Compuestos derivados de piperidinas sustituidas, inhibidores de la dna-girasa y/o topoisomerasa iv; procedimeinto para su preparacion; composiicon farmaceutica que comprende estos compustos y su uso en el tratamiento de una infeccion bacteriana.
BRPI0912112A2 (pt) agente para suprimir um efeito indesejável de um analgésico do tipo opióide, agente terapêutico e/ou preventivo para dor, kit, composição farmacêutica, métodos para suprimir um efeito indesejável de um opióide, e para tratar e/ou prevenir a dor, uso de um composto e um opióide, composto, e, combinação
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
MX2008008413A (es) Composicion farmaceutica para el tratamiento de las enfermedades de las uñas.
UY30915A1 (es) Método de tratamiento de canceres
BR112016009749A8 (pt) hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide